IL17C and Alzheimer disease: Therefore, the therapy directed against IL-17A in patients with AD may inhibit Th2-dependent cytokine inflammation, reduce IgE levels, and lead to reduction of epidermal barrier dysfunction [57], and suppress not only Th2, but also Th17/Th22, response against IL-17C.